The focus will initially be on creating computational and digital pathology products, as well as AI-assisted algorithms.

Danaher Corporation DHR recently partnered with AstraZeneca PLC AZN to develop and market novel diagnostic tools aimed at ...

Danaher (NYSE:DHR) recently announced a collaboration with AstraZeneca to develop innovative diagnostic tools, possibly adding momentum to its 1.59% share price increase over the past week. However, ...

Danaher and AstraZeneca have formed a partnership to develop diagnostic tools that help clinicians better determine which patients would benefit from precision medicine treatments.

Danaher has entered a partnership with AstraZeneca to scale precision medicine, including developing the next generation of AI-powered di ...

Danaher Corporation (NYSE:DHR) and AstraZeneca PLC (NASDAQ:AZN) have announced a major partnership to accelerate the development and commercialization of advanced diagnostic tools aimed at ...

AstraZeneca (LSE:AZN) recently announced promising clinical trial results for ENHERTU, which may reflect its ongoing ...

The partnership between Danaher and AstraZeneca reflects a shared commitment to innovation in the field of precision medicine, with the goal of delivering improved outcomes for patients globally.

The companies will develop and commercialize diagnostic tools to help clinicians determine which patients would benefit from precision medicine treatments.

Last week, readers were most interested in a story about what's up Roche's sleeve as it talked about its plans during its investor day.

Danaher and AstraZeneca have formed a partnership to develop diagnostic tools that help clinicians better determine which patients would benefit from precision medicine treatments. The venture ...

Danaher Corporation DHR recently partnered with AstraZeneca PLC AZN to develop and market novel diagnostic tools aimed at improving patient selection for precision medicine treatments. Based in ...